Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Diagnostics' ThyGenX Test

PDI's molecular diagnostic subsidiary, Interpace Diagnostics, has launched a next-generation sequencing-based panel to assess cancer risk of thyroid nodules. The test, called ThyGenX, is an eight-gene panel to help physicians distinguish between benign and malignant genotypes in indeterminate thyroid nodules.